Niguldipine - DrugBank

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name

Niguldipine

Accession Number

DB09239

Type

Small Molecule

Groups

Experimental

Description

Niguldipine is a calcium channel blocker and a1-adrenergic receptor antagonist.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

Not Available

External IDs

Not Available

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Niguldipine hydrochloride	1G8C7QS9SR	113145-69-0	MHOSUIMBPQVOEU-WAQYZQTGSA-N	Details

Products

Not Available

International Brands

Not Available

Brand mixtures

Not Available

Categories

UNII

Z81N45O25Z

CAS number

113165-32-5

Weight

Average: 609.723
Monoisotopic: 609.283885988

Chemical Formula

C₃₆H₃₉N₃O₆

InChI Key

SVJMLYUFVDMUHP-XIFFEERXSA-N

InChI

InChI=1S/C36H39N3O6/c1-25-31(34(40)44-3)33(27-12-10-17-30(24-27)39(42)43)32(26(2)37-25)35(41)45-23-11-20-38-21-18-36(19-22-38,28-13-6-4-7-14-28)29-15-8-5-9-16-29/h4-10,12-17,24,33,37H,11,18-23H2,1-3H3/t33-/m0/s1

IUPAC Name

3-[3-(4,4-diphenylpiperidin-1-yl)propyl] 5-methyl (4S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

SMILES

[H]N1C(C)=C([[email protected]](C2=CC(=CC=C2)[N+]([O-])=O)C(C(=O)OCCCN2CCC(CC2)(C2=CC=CC=C2)C2=CC=CC=C2)=C1C)C(=O)OC

Pharmacology

Indication

Not Available

Structured Indications

Not Available

Pharmacodynamics

Not Available

Mechanism of action

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Alpha-1A adrenergic receptor	Protein	unknown	antagonist	Human	P35348	details

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
2-HYDROXY-1,4-NAPHTHOQUINONE	The risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Niguldipine.	Experimental
2-mercaptobenzothiazole	The risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Niguldipine.	Vet Approved
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline	7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Niguldipine.	Experimental
Acebutolol	Acebutolol may increase the hypotensive activities of Niguldipine.	Approved
Acetyldigitoxin	Acetyldigitoxin may decrease the cardiotoxic activities of Niguldipine.	Approved
Alfuzosin	Alfuzosin may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Aliskiren	Aliskiren may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Alprenolol	Alprenolol may increase the hypotensive activities of Niguldipine.	Approved, Withdrawn
Ambrisentan	Niguldipine may increase the hypotensive activities of Ambrisentan.	Approved, Investigational
Amifostine	Niguldipine may increase the hypotensive activities of Amifostine.	Approved, Investigational
Amlodipine	Amlodipine may increase the hypotensive activities of Niguldipine.	Approved
Amobarbital	The metabolism of Niguldipine can be increased when combined with Amobarbital.	Approved, Illicit
Amorolfine	The risk or severity of adverse effects can be increased when Amorolfine is combined with Niguldipine.	Approved
Amphotericin B	The risk or severity of adverse effects can be increased when Amphotericin B is combined with Niguldipine.	Approved, Investigational
Anidulafungin	The risk or severity of adverse effects can be increased when Anidulafungin is combined with Niguldipine.	Approved, Investigational
Artemether	The risk or severity of adverse effects can be increased when Artemether is combined with Niguldipine.	Approved
Atenolol	Atenolol may increase the hypotensive activities of Niguldipine.	Approved
Atosiban	The risk or severity of adverse effects can be increased when Niguldipine is combined with Atosiban.	Approved
Atracurium besylate	Niguldipine may increase the neuromuscular blocking activities of Atracurium besylate.	Approved
Bafilomycin A1	The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Niguldipine.	Experimental
Barbexaclone	The metabolism of Niguldipine can be increased when combined with Barbexaclone.	Experimental
Barbital	The metabolism of Niguldipine can be increased when combined with Barbital.	Illicit
Benazepril	Benazepril may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Bendroflumethiazide	Bendroflumethiazide may increase the hypotensive activities of Niguldipine.	Approved
Benmoxin	Benmoxin may increase the hypotensive activities of Niguldipine.	Withdrawn
Benzoic Acid	The risk or severity of adverse effects can be increased when Benzoic Acid is combined with Niguldipine.	Approved
Bepridil	Bepridil may increase the hypotensive activities of Niguldipine.	Approved, Withdrawn
Betaxolol	Betaxolol may increase the hypotensive activities of Niguldipine.	Approved
Bethanidine	Bethanidine may increase the hypotensive activities of Niguldipine.	Approved
Bevacizumab	Bevacizumab may increase the cardiotoxic activities of Niguldipine.	Approved, Investigational
Bifonazole	The risk or severity of adverse effects can be increased when Bifonazole is combined with Niguldipine.	Approved
Bimatoprost	Bimatoprost may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Bisoprolol	Bisoprolol may increase the hypotensive activities of Niguldipine.	Approved
Bosentan	Bosentan may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Bretylium	Bretylium may increase the hypotensive activities of Niguldipine.	Approved
Brimonidine	Brimonidine may increase the hypotensive activities of Niguldipine.	Approved
Brimonidine	Brimonidine may increase the antihypertensive activities of Niguldipine.	Approved
Bucindolol	Bucindolol may increase the hypotensive activities of Niguldipine.	Investigational
Bupranolol	Bupranolol may increase the hypotensive activities of Niguldipine.	Approved
Butenafine	The risk or severity of adverse effects can be increased when Butenafine is combined with Niguldipine.	Approved
Butoconazole	The risk or severity of adverse effects can be increased when Butoconazole is combined with Niguldipine.	Approved
Cabazitaxel	The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Niguldipine.	Approved
Calcium	The therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium.	Nutraceutical
Calcium Acetate	The therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium Acetate.	Approved
Calcium Carbonate	The therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium carbonate.	Approved
Calcium Chloride	The therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium Chloride.	Approved
Calcium Citrate	The therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium citrate.	Approved
Calcium glubionate	The therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium glubionate.	Approved
Calcium Gluceptate	The therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium Gluceptate.	Approved
Calcium gluconate	The therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium gluconate.	Approved, Vet Approved
Candesartan	Candesartan may increase the hypotensive activities of Niguldipine.	Approved
Candicidin	The risk or severity of adverse effects can be increased when Candicidin is combined with Niguldipine.	Withdrawn
Candoxatril	Candoxatril may increase the hypotensive activities of Niguldipine.	Experimental
Capric acid	The risk or severity of adverse effects can be increased when Decanoic Acid is combined with Niguldipine.	Experimental
Captopril	Captopril may increase the hypotensive activities of Niguldipine.	Approved
Carbomycin	The metabolism of Niguldipine can be decreased when combined with Carbomycin.	Vet Approved
Caroxazone	Caroxazone may increase the hypotensive activities of Niguldipine.	Withdrawn
Carteolol	Carteolol may increase the hypotensive activities of Niguldipine.	Approved
Carvedilol	Carvedilol may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Caspofungin	The risk or severity of adverse effects can be increased when Caspofungin is combined with Niguldipine.	Approved
Celiprolol	Celiprolol may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Cerulenin	The risk or severity of adverse effects can be increased when Cerulenin is combined with Niguldipine.	Approved
Chlorothiazide	Chlorothiazide may increase the hypotensive activities of Niguldipine.	Approved, Vet Approved
Chloroxine	The risk or severity of adverse effects can be increased when Chloroxine is combined with Niguldipine.	Approved
Chlorthalidone	Chlorthalidone may increase the hypotensive activities of Niguldipine.	Approved
Ciclopirox	The risk or severity of adverse effects can be increased when Ciclopirox is combined with Niguldipine.	Approved, Investigational
Cilazapril	Cilazapril may increase the hypotensive activities of Niguldipine.	Approved
Cimetidine	The serum concentration of Niguldipine can be increased when it is combined with Cimetidine.	Approved
Clarithromycin	The metabolism of Niguldipine can be decreased when combined with Clarithromycin.	Approved
Clonidine	Clonidine may increase the hypotensive activities of Niguldipine.	Approved
Clopidogrel	The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Niguldipine.	Approved, Nutraceutical
Clotrimazole	The risk or severity of adverse effects can be increased when Clotrimazole is combined with Niguldipine.	Approved, Vet Approved
Cordycepin	The risk or severity of adverse effects can be increased when Cordycepin is combined with Niguldipine.	Investigational
Cryptenamine	Cryptenamine may increase the hypotensive activities of Niguldipine.	Approved
Cyclophosphamide	Cyclophosphamide may increase the cardiotoxic activities of Niguldipine.	Approved, Investigational
Cyclosporine	The risk or severity of adverse effects can be increased when Cyclosporine is combined with Niguldipine.	Approved, Investigational, Vet Approved
Cyclothiazide	Cyclothiazide may increase the hypotensive activities of Niguldipine.	Approved
Dapoxetine	Dapoxetine may increase the orthostatic hypotensive activities of Niguldipine.	Investigational
Debrisoquin	Debrisoquin may increase the hypotensive activities of Niguldipine.	Approved
Deserpidine	Niguldipine may increase the hypotensive activities of Deserpidine.	Approved
Deslanoside	Deslanoside may decrease the cardiotoxic activities of Niguldipine.	Approved
Diazoxide	Diazoxide may increase the hypotensive activities of Niguldipine.	Approved
Digitoxin	Digitoxin may decrease the cardiotoxic activities of Niguldipine.	Approved
Digoxin	Digoxin may decrease the cardiotoxic activities of Niguldipine.	Approved
Dihydralazine	Niguldipine may increase the hypotensive activities of Dihydralazine.	Investigational
Diltiazem	Diltiazem may increase the hypotensive activities of Niguldipine.	Approved
Docetaxel	The risk or severity of adverse effects can be increased when Docetaxel is combined with Niguldipine.	Approved, Investigational
Dorzolamide	Dorzolamide may increase the hypotensive activities of Niguldipine.	Approved
Doxazosin	Doxazosin may increase the hypotensive activities of Niguldipine.	Approved
Econazole	The risk or severity of adverse effects can be increased when Econazole is combined with Niguldipine.	Approved
Efavirenz	The serum concentration of Niguldipine can be decreased when it is combined with Efavirenz.	Approved, Investigational
Efinaconazole	The risk or severity of adverse effects can be increased when Efinaconazole is combined with Niguldipine.	Approved
Efonidipine	Efonidipine may increase the hypotensive activities of Niguldipine.	Approved
Enalapril	Enalapril may increase the hypotensive activities of Niguldipine.	Approved, Vet Approved
Enalaprilat	Niguldipine may increase the hypotensive activities of Enalaprilat.	Approved
Epoprostenol	Epoprostenol may increase the hypotensive activities of Niguldipine.	Approved
Eprosartan	Eprosartan may increase the hypotensive activities of Niguldipine.	Approved
Erythromycin	The metabolism of Niguldipine can be decreased when combined with Erythromycin.	Approved, Vet Approved
Felodipine	Felodipine may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Fenoldopam	Fenoldopam may increase the hypotensive activities of Niguldipine.	Approved
Fluconazole	The serum concentration of Niguldipine can be increased when it is combined with Fluconazole.	Approved
Flucytosine	The risk or severity of adverse effects can be increased when Flucytosine is combined with Niguldipine.	Approved
Fosinopril	Fosinopril may increase the hypotensive activities of Niguldipine.	Approved
Fosphenytoin	The serum concentration of Fosphenytoin can be increased when it is combined with Niguldipine.	Approved
Furazolidone	Furazolidone may increase the hypotensive activities of Niguldipine.	Approved, Vet Approved
Glyphosate	The risk or severity of adverse effects can be increased when Glyphosate is combined with Niguldipine.	Experimental
Griseofulvin	The risk or severity of adverse effects can be increased when Griseofulvin is combined with Niguldipine.	Approved, Vet Approved
Guanabenz	Guanabenz may increase the hypotensive activities of Niguldipine.	Approved
Guanadrel	Guanadrel may increase the hypotensive activities of Niguldipine.	Approved
Guanethidine	Guanethidine may increase the hypotensive activities of Niguldipine.	Approved
Guanfacine	Guanfacine may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Haloprogin	The risk or severity of adverse effects can be increased when Haloprogin is combined with Niguldipine.	Approved, Withdrawn
Hexamethonium	Hexamethonium may increase the hypotensive activities of Niguldipine.	Experimental
Hexetidine	The risk or severity of adverse effects can be increased when Hexetidine is combined with Niguldipine.	Approved
Hexobarbital	The metabolism of Niguldipine can be increased when combined with Hexobarbital.	Approved
Hydracarbazine	Hydracarbazine may increase the hypotensive activities of Niguldipine.	Experimental
Hydralazine	Hydralazine may increase the hypotensive activities of Niguldipine.	Approved
Hydrochlorothiazide	Hydrochlorothiazide may increase the hypotensive activities of Niguldipine.	Approved, Vet Approved
Hydroflumethiazide	Hydroflumethiazide may increase the hypotensive activities of Niguldipine.	Approved
Iloprost	Iloprost may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Imidapril	Niguldipine may increase the hypotensive activities of Imidapril.	Investigational
Indapamide	Indapamide may increase the hypotensive activities of Niguldipine.	Approved
Indenolol	Indenolol may increase the hypotensive activities of Niguldipine.	Withdrawn
Indoramin	Indoramin may increase the hypotensive activities of Niguldipine.	Withdrawn
Iproclozide	Iproclozide may increase the hypotensive activities of Niguldipine.	Withdrawn
Iproniazid	Iproniazid may increase the hypotensive activities of Niguldipine.	Withdrawn
Irbesartan	Irbesartan may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Isocarboxazid	Isocarboxazid may increase the hypotensive activities of Niguldipine.	Approved
Isoconazole	The risk or severity of adverse effects can be increased when Isoconazole is combined with Niguldipine.	Approved
Isradipine	Isradipine may increase the hypotensive activities of Niguldipine.	Approved
Itraconazole	The risk or severity of adverse effects can be increased when Itraconazole is combined with Niguldipine.	Approved, Investigational
Josamycin	The metabolism of Niguldipine can be decreased when combined with Josamycin.	Approved
Ketanserin	Niguldipine may increase the hypotensive activities of Ketanserin.	Investigational
Ketoconazole	The risk or severity of adverse effects can be increased when Ketoconazole is combined with Niguldipine.	Approved, Investigational
Kitasamycin	The metabolism of Niguldipine can be decreased when combined with Kitasamycin.	Experimental
Labetalol	Labetalol may increase the hypotensive activities of Niguldipine.	Approved
Lacidipine	Lacidipine may increase the hypotensive activities of Niguldipine.	Approved
Latanoprost	Latanoprost may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Lercanidipine	Lercanidipine may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Lisinopril	Lisinopril may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Lofexidine	Lofexidine may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Losartan	Losartan may increase the hypotensive activities of Niguldipine.	Approved
Macitentan	Niguldipine may increase the hypotensive activities of Macitentan.	Approved
Magnesium Hydroxide	The risk or severity of adverse effects can be increased when Niguldipine is combined with Magnesium hydroxide.	Approved
Magnesium oxide	The risk or severity of adverse effects can be increased when Niguldipine is combined with Magnesium oxide.	Approved
Magnesium salicylate	The risk or severity of adverse effects can be increased when Niguldipine is combined with Magnesium salicylate.	Approved
Magnesium Sulfate	The risk or severity of adverse effects can be increased when Niguldipine is combined with Magnesium Sulfate.	Approved, Vet Approved
Manidipine	Manidipine may increase the hypotensive activities of Niguldipine.	Approved
Mebanazine	Mebanazine may increase the hypotensive activities of Niguldipine.	Withdrawn
Mecamylamine	Mecamylamine may increase the hypotensive activities of Niguldipine.	Approved
Methohexital	The metabolism of Niguldipine can be increased when combined with Methohexital.	Approved
Methyldopa	Methyldopa may increase the hypotensive activities of Niguldipine.	Approved
Methylene blue	Methylene blue may increase the hypotensive activities of Niguldipine.	Investigational
Methylphenidate	Methylphenidate may decrease the antihypertensive activities of Niguldipine.	Approved, Investigational
Methylphenobarbital	The metabolism of Niguldipine can be increased when combined with Methylphenobarbital.	Approved
Metipranolol	Metipranolol may increase the hypotensive activities of Niguldipine.	Approved
Metolazone	Metolazone may increase the hypotensive activities of Niguldipine.	Approved
Metoprolol	Metoprolol may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Metyrosine	Niguldipine may increase the hypotensive activities of Metyrosine.	Approved
Mevastatin	The risk or severity of adverse effects can be increased when Mevastatin is combined with Niguldipine.	Experimental
Mibefradil	Mibefradil may increase the hypotensive activities of Niguldipine.	Withdrawn
Micafungin	The risk or severity of adverse effects can be increased when Micafungin is combined with Niguldipine.	Approved, Investigational
Miconazole	The risk or severity of adverse effects can be increased when Miconazole is combined with Niguldipine.	Approved, Investigational, Vet Approved
Miltefosine	The risk or severity of adverse effects can be increased when Miltefosine is combined with Niguldipine.	Approved
Minaprine	Minaprine may increase the hypotensive activities of Niguldipine.	Approved
Minoxidil	Minoxidil may increase the hypotensive activities of Niguldipine.	Approved
Mivacurium	Niguldipine may increase the neuromuscular blocking activities of Mivacurium.	Approved
Moclobemide	Moclobemide may increase the hypotensive activities of Niguldipine.	Approved
Moexipril	Moexipril may increase the hypotensive activities of Niguldipine.	Approved
Molsidomine	Molsidomine may increase the hypotensive activities of Niguldipine.	Approved
Monensin	The risk or severity of adverse effects can be increased when Monensin is combined with Niguldipine.	Vet Approved
Moxonidine	Niguldipine may increase the hypotensive activities of Moxonidine.	Approved
Myxothiazol	The risk or severity of adverse effects can be increased when Myxothiazol is combined with Niguldipine.	Experimental
Nadolol	Nadolol may increase the hypotensive activities of Niguldipine.	Approved
Nafcillin	The metabolism of Niguldipine can be increased when combined with Nafcillin.	Approved
Naftifine	The risk or severity of adverse effects can be increased when Naftifine is combined with Niguldipine.	Approved
Naftopidil	Niguldipine may increase the hypotensive activities of Naftopidil.	Investigational
Natamycin	The risk or severity of adverse effects can be increased when Natamycin is combined with Niguldipine.	Approved
Nebivolol	Nebivolol may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Nialamide	Nialamide may increase the hypotensive activities of Niguldipine.	Withdrawn
Nicardipine	Nicardipine may increase the hypotensive activities of Niguldipine.	Approved
Nicorandil	Nicorandil may increase the hypotensive activities of Niguldipine.	Approved
Nilvadipine	Nilvadipine may increase the hypotensive activities of Niguldipine.	Approved
Nimodipine	Nimodipine may increase the hypotensive activities of Niguldipine.	Approved
Nisoldipine	Nisoldipine may increase the hypotensive activities of Niguldipine.	Approved
Nitrendipine	Nitrendipine may increase the hypotensive activities of Niguldipine.	Approved
Nitroprusside	Niguldipine may increase the hypotensive activities of Nitroprusside.	Approved
Nitroxoline	The risk or severity of adverse effects can be increased when Nitroxoline is combined with Niguldipine.	Approved
Nystatin	The risk or severity of adverse effects can be increased when Nystatin is combined with Niguldipine.	Approved, Vet Approved
Obinutuzumab	Niguldipine may increase the hypotensive activities of Obinutuzumab.	Approved
Octamoxin	Octamoxin may increase the hypotensive activities of Niguldipine.	Withdrawn
Oleandomycin	The metabolism of Niguldipine can be decreased when combined with Oleandomycin.	Vet Approved
Oleandrin	Anvirzel may decrease the cardiotoxic activities of Niguldipine.	Experimental
Olmesartan	Olmesartan may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Omapatrilat	Omapatrilat may increase the hypotensive activities of Niguldipine.	Investigational
Ouabain	Ouabain may decrease the cardiotoxic activities of Niguldipine.	Approved
Oxiconazole	The risk or severity of adverse effects can be increased when Oxiconazole is combined with Niguldipine.	Approved
Oxprenolol	Oxprenolol may increase the hypotensive activities of Niguldipine.	Approved
Paclitaxel	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Niguldipine.	Approved, Vet Approved
pafuramidine	The risk or severity of adverse effects can be increased when pafuramidine is combined with Niguldipine.	Investigational
Pargyline	Pargyline may increase the hypotensive activities of Niguldipine.	Approved
Penbutolol	Penbutolol may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Pentamidine	The risk or severity of adverse effects can be increased when Pentamidine is combined with Niguldipine.	Approved
Pentobarbital	The metabolism of Niguldipine can be increased when combined with Pentobarbital.	Approved, Vet Approved
Pentolinium	Pentolinium may increase the hypotensive activities of Niguldipine.	Approved
Pentoxifylline	Pentoxifylline may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Perindopril	Perindopril may increase the hypotensive activities of Niguldipine.	Approved
Phenelzine	Phenelzine may increase the hypotensive activities of Niguldipine.	Approved
Pheniprazine	Pheniprazine may increase the hypotensive activities of Niguldipine.	Withdrawn
Phenobarbital	The metabolism of Niguldipine can be increased when combined with Phenobarbital.	Approved
Phenoxybenzamine	Phenoxybenzamine may increase the hypotensive activities of Niguldipine.	Approved
Phenoxypropazine	Phenoxypropazine may increase the hypotensive activities of Niguldipine.	Withdrawn
Phentolamine	Phentolamine may increase the hypotensive activities of Niguldipine.	Approved
Phenytoin	The serum concentration of Phenytoin can be increased when it is combined with Niguldipine.	Approved, Vet Approved
Pinacidil	Pinacidil may increase the hypotensive activities of Niguldipine.	Withdrawn
Pindolol	Pindolol may increase the hypotensive activities of Niguldipine.	Approved
Pirlindole	Pirlindole may increase the hypotensive activities of Niguldipine.	Approved
Pivhydrazine	Pivhydrazine may increase the hypotensive activities of Niguldipine.	Withdrawn
Polythiazide	Polythiazide may increase the hypotensive activities of Niguldipine.	Approved
Posaconazole	The risk or severity of adverse effects can be increased when Posaconazole is combined with Niguldipine.	Approved, Investigational, Vet Approved
Prazosin	Prazosin may increase the hypotensive activities of Niguldipine.	Approved
Primidone	The metabolism of Niguldipine can be increased when combined with Primidone.	Approved, Vet Approved
Propranolol	Propranolol may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Quinapril	Quinapril may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Quinine	Quinine may increase the hypotensive activities of Niguldipine.	Approved
Radicicol	The risk or severity of adverse effects can be increased when Radicicol is combined with Niguldipine.	Experimental
Ramipril	Ramipril may increase the hypotensive activities of Niguldipine.	Approved
Rapacuronium	Niguldipine may increase the neuromuscular blocking activities of Rapacuronium.	Withdrawn
Rasagiline	Rasagiline may increase the hypotensive activities of Niguldipine.	Approved
Remikiren	Remikiren may increase the hypotensive activities of Niguldipine.	Approved
Rescinnamine	Niguldipine may increase the hypotensive activities of Rescinnamine.	Approved
Reserpine	Reserpine may increase the hypotensive activities of Niguldipine.	Approved
Rifabutin	The serum concentration of Niguldipine can be decreased when it is combined with Rifabutin.	Approved
Rifampicin	The serum concentration of Niguldipine can be decreased when it is combined with Rifampicin.	Approved
Rifapentine	The serum concentration of Niguldipine can be decreased when it is combined with Rifapentine.	Approved
Rilmenidine	Niguldipine may increase the hypotensive activities of Rilmenidine.	Investigational
Riociguat	Niguldipine may increase the hypotensive activities of Riociguat.	Approved
Rituximab	Niguldipine may increase the hypotensive activities of Rituximab.	Approved
Safrazine	Safrazine may increase the hypotensive activities of Niguldipine.	Withdrawn
Salicylhydroxamic Acid	The risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Niguldipine.	Experimental
Salicylic acid	The risk or severity of adverse effects can be increased when Salicylic acid is combined with Niguldipine.	Approved, Vet Approved
Saprisartan	Saprisartan may increase the hypotensive activities of Niguldipine.	Experimental
Secobarbital	The metabolism of Niguldipine can be increased when combined with Secobarbital.	Approved, Vet Approved
Selegiline	Selegiline may increase the hypotensive activities of Niguldipine.	Approved, Investigational, Vet Approved
Selexipag	Niguldipine may increase the hypotensive activities of Selexipag.	Approved
Sertaconazole	The risk or severity of adverse effects can be increased when Sertaconazole is combined with Niguldipine.	Approved
Sildenafil	Sildenafil may increase the antihypertensive activities of Niguldipine.	Approved, Investigational
Silodosin	Silodosin may increase the hypotensive activities of Niguldipine.	Approved
Sinefungin	The risk or severity of adverse effects can be increased when Sinefungin is combined with Niguldipine.	Experimental
Sirolimus	The risk or severity of adverse effects can be increased when Sirolimus is combined with Niguldipine.	Approved, Investigational
Sitaxentan	Niguldipine may increase the hypotensive activities of Sitaxentan.	Approved, Investigational, Withdrawn
Solithromycin	The metabolism of Niguldipine can be decreased when combined with Solithromycin.	Investigational
Spirapril	Spirapril may increase the hypotensive activities of Niguldipine.	Approved
Sulconazole	The risk or severity of adverse effects can be increased when Sulconazole is combined with Niguldipine.	Approved
Tadalafil	Tadalafil may increase the antihypertensive activities of Niguldipine.	Approved, Investigational
Tamsulosin	Tamsulosin may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Tavaborole	The risk or severity of adverse effects can be increased when Tavaborole is combined with Niguldipine.	Approved
Telithromycin	The metabolism of Niguldipine can be decreased when combined with Telithromycin.	Approved
Telmisartan	Telmisartan may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Temocapril	Temocapril may increase the hypotensive activities of Niguldipine.	Experimental, Investigational
Terazosin	Terazosin may increase the hypotensive activities of Niguldipine.	Approved
Terbinafine	The risk or severity of adverse effects can be increased when Terbinafine is combined with Niguldipine.	Approved, Investigational, Vet Approved
Terconazole	The risk or severity of adverse effects can be increased when Terconazole is combined with Niguldipine.	Approved
Terlipressin	Terlipressin may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Thiamylal	The metabolism of Niguldipine can be increased when combined with Thiamylal.	Approved, Vet Approved
Thiopental	The metabolism of Niguldipine can be increased when combined with Thiopental.	Approved, Vet Approved
Thymol	The risk or severity of adverse effects can be increased when Thymol is combined with Niguldipine.	Approved
Tibolone	Tibolone may increase the hypotensive activities of Niguldipine.	Approved
Ticrynafen	Ticrynafen may increase the hypotensive activities of Niguldipine.	Withdrawn
Timolol	Timolol may increase the hypotensive activities of Niguldipine.	Approved
Tioconazole	The risk or severity of adverse effects can be increased when Tioconazole is combined with Niguldipine.	Approved
Tolazoline	Tolazoline may increase the hypotensive activities of Niguldipine.	Approved, Vet Approved
Tolnaftate	The risk or severity of adverse effects can be increased when Tolnaftate is combined with Niguldipine.	Approved, Vet Approved
Toloxatone	Toloxatone may increase the hypotensive activities of Niguldipine.	Approved
Torasemide	Torasemide may increase the hypotensive activities of Niguldipine.	Approved
Trandolapril	Trandolapril may increase the hypotensive activities of Niguldipine.	Approved
Trans-2-Phenylcyclopropylamine	Trans-2-Phenylcyclopropylamine may increase the hypotensive activities of Niguldipine.	Experimental
Tranylcypromine	Tranylcypromine may increase the hypotensive activities of Niguldipine.	Approved
Trastuzumab	Trastuzumab may increase the cardiotoxic activities of Niguldipine.	Approved, Investigational
Travoprost	Travoprost may increase the hypotensive activities of Niguldipine.	Approved
Treprostinil	Treprostinil may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Trichlormethiazide	Trichlormethiazide may increase the hypotensive activities of Niguldipine.	Approved, Vet Approved
Trimazosin	Trimazosin may increase the hypotensive activities of Niguldipine.	Experimental
Trimethaphan	Trimethaphan may increase the hypotensive activities of Niguldipine.	Approved
Trimetrexate	The risk or severity of adverse effects can be increased when Trimetrexate is combined with Niguldipine.	Approved, Investigational
Tylosin	The metabolism of Niguldipine can be decreased when combined with Tylosin.	Vet Approved
Udenafil	Udenafil may increase the antihypertensive activities of Niguldipine.	Approved, Investigational
Unoprostone	Unoprostone may increase the hypotensive activities of Niguldipine.	Approved
Valsartan	Valsartan may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Vardenafil	Vardenafil may increase the antihypertensive activities of Niguldipine.	Approved
Vinpocetine	Niguldipine may increase the hypotensive activities of Vinpocetine.	Investigational
Voriconazole	The risk or severity of adverse effects can be increased when Voriconazole is combined with Niguldipine.	Approved, Investigational
Xylometazoline	Xylometazoline may increase the hypotensive activities of Niguldipine.	Approved
Yohimbine	Yohimbine may decrease the antihypertensive activities of Niguldipine.	Approved, Vet Approved

Food Interactions

Not Available

References

Synthesis Reference

Not Available

General References

Boer R, Grassegger A, Schudt C, Glossmann H: (+)-Niguldipine binds with very high affinity to Ca2+ channels and to a subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1989 May 11;172(2):131-45. [PubMed:2548881 ]

External Links

Resource	Link
ChemSpider	54630
BindingDB	50453799
ChEBI	103931
ChEMBL	CHEMBL405355
Wikipedia	Niguldipine

ATC Codes

Not Available

AHFS Codes

Not Available

PDB Entries

Not Available

FDA label

Not Available

MSDS

Not Available

Clinical Trials

Not Available

Properties

State

Solid

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.000113 mg/mL	ALOGPS
logP	6.27	ALOGPS
logP	5.6	ChemAxon
logS	-6.7	ALOGPS
pKa (Strongest Acidic)	19.47	ChemAxon
pKa (Strongest Basic)	9.59	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	6	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	111.01 Å²	ChemAxon
Rotatable Bond Count	12	ChemAxon
Refractivity	185.9 m³·mol^-1	ChemAxon
Polarizability	66.15 Å³	ChemAxon
Number of Rings	5	ChemAxon
Bioavailability	0	ChemAxon
Rule of Five	No	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.

Kingdom

Organic compounds

Super Class

Benzenoids

Class

Benzene and substituted derivatives

Sub Class

Diphenylmethanes

Direct Parent

Diphenylmethanes

Alternative Parents

Phenylpiperidines / Dihydropyridinecarboxylic acids and derivatives / Nitrobenzenes / Nitroaromatic compounds / Aralkylamines / Dicarboxylic acids and derivatives / Vinylogous amides / Enoate esters / Methyl esters / Amino acids and derivatives

Substituents

Diphenylmethane / Phenylpiperidine / Dihydropyridinecarboxylic acid derivative / Nitrobenzene / Nitroaromatic compound / Dihydropyridine / Aralkylamine / Piperidine / Dicarboxylic acid or derivatives / Hydropyridine

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

Not Available

Targets

Details

1. Alpha-1A adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: antagonist

General Function:: Protein heterodimerization activity
Specific Function:: This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:: ADRA1A
Uniprot ID:: P35348
Uniprot Name:: Alpha-1A adrenergic receptor
Molecular Weight:: 51486.005 Da

References

Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R, Lepor H, Hartig PR, Weinshank RL, Branchek TA, et al.: The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994 Apr;45(4):703-8. [PubMed:8183249 ]

Drug created on October 23, 2015 11:02 / Updated on September 01, 2017 12:03

Structure for DB09239 (Niguldipine)

Targets

References